Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08IGF
|
||||
| Former ID |
DNC000852
|
||||
| Drug Name |
L-685,818
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [537853] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C43H69NO13
|
||||
| Canonical SMILES |
CCC1C=C(C(C(CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C<br />(C(CC1=O)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC)C)O)C
|
||||
| InChI |
1S/C43H69NO13/c1-10-29-18-23(2)37(48)24(3)19-35(54-8)39-36(55-9)20-26(5)43(52,57-39)40(49)41(50)44-16-12-11-13-30(44)42(51)56-38(27(6)32(46)22-33(29)47)25(4)17-28-14-15-31(45)34(21-28)53-7/h17-18,24,26-32,34-39,45-46,48,52H,10-16,19-22H2,1-9H3/b23-18+,25-17+/t24-,26+,27+,28?,29+,30-,31+,32-,34+,35-,36-,37+,38+,39+,43+/m0/s1
|
||||
| InChIKey |
NOQNPBXNHMZMTC-AFKHLADTSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Calcineurin | Target Info | Inhibitor | [534961] | |
| Kappa-type opioid receptor | Target Info | Antagonist | [537853] | ||
| KEGG Pathway | MAPK signaling pathway | ||||
| Calcium signaling pathway | |||||
| cGMP-PKG signaling pathway | |||||
| Oocyte meiosis | |||||
| Apoptosis | |||||
| Wnt signaling pathway | |||||
| Axon guidance | |||||
| VEGF signaling pathway | |||||
| Osteoclast differentiation | |||||
| Natural killer cell mediated cytotoxicity | |||||
| T cell receptor signaling pathway | |||||
| B cell receptor signaling pathway | |||||
| Long-term potentiation | |||||
| Glutamatergic synapse | |||||
| Dopaminergic synapse | |||||
| Oxytocin signaling pathway | |||||
| Glucagon signaling pathway | |||||
| Alzheimer's disease | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Amphetamine addiction | |||||
| Tuberculosis | |||||
| HTLV-I infectionhsa04080:Neuroactive ligand-receptor interaction | |||||
| WikiPathways | Mitochondrial Gene Expression | ||||
| MAPK Signaling Pathway | |||||
| G Protein Signaling Pathways | |||||
| Cardiac Hypertrophic Response | |||||
| Fc epsilon receptor (FCERI) signaling | |||||
| Signaling by the B Cell Receptor (BCR) | |||||
| T-Cell Receptor and Co-stimulatory Signaling | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Spinal Cord Injury | |||||
| Alzheimers Disease | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| Opioid Signalling | |||||
| MicroRNAs in cardiomyocyte hypertrophy | |||||
| Physiological and Pathological Hypertrophy of the HeartWP455:GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| Ref 534961 | Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother. 2000 Mar;44(3):739-46. | ||||
| Ref 537853 | FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. J Biol Chem. 1993 May 25;268(15):11335-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.